Limitations of current Parkinson's disease therapy
Identifieur interne : 003132 ( Main/Exploration ); précédent : 003131; suivant : 003133Limitations of current Parkinson's disease therapy
Auteurs : Olivier Rascol [France] ; Pierre Payoux [France] ; Fabienne Ory [France] ; Joaquim J. Ferreira [France, Portugal] ; Christine Brefel-Courbon [France] ; Jean-Louis Montastruc [France]Source :
- Annals of Neurology [ 0364-5134 ] ; 2003.
Descripteurs français
- Pascal (Inist)
- Wicri :
English descriptors
- KwdEn :
- Agonist, Amine oxidase (flavin-containing), Antiparkinson Agents (adverse effects), Antiparkinson Agents (classification), Antiparkinson Agents (therapeutic use), Antiparkinson agent, Catechol O-methyltransferase, Chemotherapy, Cognition Disorders (chemically induced), Dopamine agonist, Dopamine receptor, Drug Resistance, Dysarthria (chemically induced), Dyskinesia, Drug-Induced (etiology), Electric Stimulation Therapy (methods), Enzyme inhibitor, Globus Pallidus (physiology), Globus Pallidus (surgery), Human, Humans, Indication, Levodopa, MAO B inhibitor, Neurosurgical Procedures, Parkinson Disease (drug therapy), Parkinson Disease (surgery), Parkinson Disease (therapy), Parkinson disease, Psychoses, Substance-Induced (etiology), Quality of Life, Selegiline, Subthalamic Nucleus (physiology), Subthalamic Nucleus (surgery), Surgery, Toxicity, Treatment.
- MESH :
- chemical , adverse effects : Antiparkinson Agents.
- chemical , classification : Antiparkinson Agents.
- chemical , therapeutic use : Antiparkinson Agents.
- chemically induced : Cognition Disorders, Dysarthria.
- drug therapy : Parkinson Disease.
- etiology : Dyskinesia, Drug-Induced, Psychoses, Substance-Induced.
- methods : Electric Stimulation Therapy.
- physiology : Globus Pallidus, Subthalamic Nucleus.
- surgery : Globus Pallidus, Parkinson Disease, Subthalamic Nucleus.
- therapy : Parkinson Disease.
- Drug Resistance, Humans, Neurosurgical Procedures, Quality of Life.
Abstract
Levodopa and other dopaminergic medications drastically improve the motor symptoms and quality of life of patients with Parkinson's disease in the early stages of the disease. However, once the “honeymoon” period has waned, usually after a few years of dopaminergic therapy, patients become progressively more disabled despite an ever more complex combination of available antiparkinsonian treatments. Sooner or later, they suffer from “dopa‐resistant” motor symptoms (speech impairment, abnormal posture, gait and balance problems), “dopa‐resistant” nonmotor signs (autonomic dysfunction, mood and cognitive impairment, sleep problems, pain) and/or drug‐related side effects (especially psychosis, motor fluctuations, and dyskinesias). Therefore, the current antiparkinsonian therapy cannot be considered as ideal with regard to both efficacy and safety. Ann Neurol 2003;53 (suppl 3):S3–S15
Url:
DOI: 10.1002/ana.10513
Affiliations:
Links toward previous steps (curation, corpus...)
- to stream Istex, to step Corpus: 001074
- to stream Istex, to step Curation: 001072
- to stream Istex, to step Checkpoint: 000C87
- to stream PubMed, to step Corpus: 001131
- to stream PubMed, to step Curation: 001090
- to stream PubMed, to step Checkpoint: 001090
- to stream Ncbi, to step Merge: 000316
- to stream Ncbi, to step Curation: 000316
- to stream Ncbi, to step Checkpoint: 000316
- to stream Main, to step Merge: 003606
- to stream PascalFrancis, to step Corpus: 000F40
- to stream PascalFrancis, to step Curation: 000494
- to stream PascalFrancis, to step Checkpoint: 000D70
- to stream Main, to step Merge: 003733
- to stream Main, to step Curation: 003132
Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Limitations of current Parkinson's disease therapy</title><author><name sortKey="Rascol, Olivier" sort="Rascol, Olivier" uniqKey="Rascol O" first="Olivier" last="Rascol">Olivier Rascol</name></author><author><name sortKey="Payoux, Pierre" sort="Payoux, Pierre" uniqKey="Payoux P" first="Pierre" last="Payoux">Pierre Payoux</name></author><author><name sortKey="Ory, Fabienne" sort="Ory, Fabienne" uniqKey="Ory F" first="Fabienne" last="Ory">Fabienne Ory</name></author><author><name sortKey="Ferreira, Joaquim J" sort="Ferreira, Joaquim J" uniqKey="Ferreira J" first="Joaquim J." last="Ferreira">Joaquim J. Ferreira</name></author><author><name sortKey="Brefel Ourbon, Christine" sort="Brefel Ourbon, Christine" uniqKey="Brefel Ourbon C" first="Christine" last="Brefel-Courbon">Christine Brefel-Courbon</name></author><author><name sortKey="Montastruc, Jean Ouis" sort="Montastruc, Jean Ouis" uniqKey="Montastruc J" first="Jean-Louis" last="Montastruc">Jean-Louis Montastruc</name></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:8375DC24A4BC4E9A05F5C375BBB7AB996C46D84E</idno><date when="2003" year="2003">2003</date><idno type="doi">10.1002/ana.10513</idno><idno type="url">https://api.istex.fr/document/8375DC24A4BC4E9A05F5C375BBB7AB996C46D84E/fulltext/pdf</idno><idno type="wicri:Area/Istex/Corpus">001074</idno><idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Corpus" wicri:corpus="ISTEX">001074</idno><idno type="wicri:Area/Istex/Curation">001072</idno><idno type="wicri:Area/Istex/Checkpoint">000C87</idno><idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Checkpoint">000C87</idno><idno type="wicri:doubleKey">0364-5134:2003:Rascol O:limitations:of:current</idno><idno type="wicri:source">PubMed</idno><idno type="RBID">pubmed:12666094</idno><idno type="wicri:Area/PubMed/Corpus">001131</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">001131</idno><idno type="wicri:Area/PubMed/Curation">001090</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">001090</idno><idno type="wicri:Area/PubMed/Checkpoint">001090</idno><idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">001090</idno><idno type="wicri:Area/Ncbi/Merge">000316</idno><idno type="wicri:Area/Ncbi/Curation">000316</idno><idno type="wicri:Area/Ncbi/Checkpoint">000316</idno><idno type="wicri:doubleKey">0364-5134:2003:Rascol O:limitations:of:current</idno><idno type="wicri:Area/Main/Merge">003606</idno><idno type="wicri:source">INIST</idno><idno type="RBID">Pascal:03-0329429</idno><idno type="wicri:Area/PascalFrancis/Corpus">000F40</idno><idno type="wicri:Area/PascalFrancis/Curation">000494</idno><idno type="wicri:Area/PascalFrancis/Checkpoint">000D70</idno><idno type="wicri:explorRef" wicri:stream="PascalFrancis" wicri:step="Checkpoint">000D70</idno><idno type="wicri:doubleKey">0364-5134:2003:Rascol O:limitations:of:current</idno><idno type="wicri:Area/Main/Merge">003733</idno><idno type="wicri:Area/Main/Curation">003132</idno><idno type="wicri:Area/Main/Exploration">003132</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Limitations of current Parkinson's disease therapy</title><author><name sortKey="Rascol, Olivier" sort="Rascol, Olivier" uniqKey="Rascol O" first="Olivier" last="Rascol">Olivier Rascol</name><affiliation wicri:level="3"><country xml:lang="fr">France</country><wicri:regionArea>Clinical Investigation Centre and Department of Clinical Pharmacology, Toulouse</wicri:regionArea><placeName><region type="region">Occitanie (région administrative)</region><region type="old region">Midi-Pyrénées</region><settlement type="city">Toulouse</settlement></placeName></affiliation><affiliation wicri:level="3"><country xml:lang="fr">France</country><wicri:regionArea>INSERM U455, Toulouse</wicri:regionArea><placeName><region type="region">Occitanie (région administrative)</region><region type="old region">Midi-Pyrénées</region><settlement type="city">Toulouse</settlement></placeName></affiliation><affiliation wicri:level="3"><country xml:lang="fr">France</country><wicri:regionArea>Laboratory of Clinical Pharmacology, Faculty of Medicine, 37 Allées J. Guesde, 31073 Toulouse Cedex</wicri:regionArea><placeName><region type="region" nuts="2">Occitanie (région administrative)</region><region type="old region" nuts="2">Midi-Pyrénées</region><settlement type="city">Toulouse</settlement></placeName></affiliation></author><author><name sortKey="Payoux, Pierre" sort="Payoux, Pierre" uniqKey="Payoux P" first="Pierre" last="Payoux">Pierre Payoux</name><affiliation wicri:level="3"><country xml:lang="fr">France</country><wicri:regionArea>INSERM U455, Toulouse</wicri:regionArea><placeName><region type="region">Occitanie (région administrative)</region><region type="old region">Midi-Pyrénées</region><settlement type="city">Toulouse</settlement></placeName></affiliation><affiliation wicri:level="3"><country xml:lang="fr">France</country><wicri:regionArea>Department of Nuclear Medicine, Toulouse</wicri:regionArea><placeName><region type="region">Occitanie (région administrative)</region><region type="old region">Midi-Pyrénées</region><settlement type="city">Toulouse</settlement></placeName></affiliation></author><author><name sortKey="Ory, Fabienne" sort="Ory, Fabienne" uniqKey="Ory F" first="Fabienne" last="Ory">Fabienne Ory</name><affiliation wicri:level="3"><country xml:lang="fr">France</country><wicri:regionArea>Clinical Investigation Centre and Department of Clinical Pharmacology, Toulouse</wicri:regionArea><placeName><region type="region">Occitanie (région administrative)</region><region type="old region">Midi-Pyrénées</region><settlement type="city">Toulouse</settlement></placeName></affiliation></author><author><name sortKey="Ferreira, Joaquim J" sort="Ferreira, Joaquim J" uniqKey="Ferreira J" first="Joaquim J." last="Ferreira">Joaquim J. Ferreira</name><affiliation wicri:level="3"><country xml:lang="fr">France</country><wicri:regionArea>Clinical Investigation Centre and Department of Clinical Pharmacology, Toulouse</wicri:regionArea><placeName><region type="region">Occitanie (région administrative)</region><region type="old region">Midi-Pyrénées</region><settlement type="city">Toulouse</settlement></placeName></affiliation><affiliation wicri:level="1"><country xml:lang="fr">Portugal</country><wicri:regionArea>Department of Neurology, Lisbon</wicri:regionArea><wicri:noRegion>Lisbon</wicri:noRegion></affiliation></author><author><name sortKey="Brefel Ourbon, Christine" sort="Brefel Ourbon, Christine" uniqKey="Brefel Ourbon C" first="Christine" last="Brefel-Courbon">Christine Brefel-Courbon</name><affiliation wicri:level="3"><country xml:lang="fr">France</country><wicri:regionArea>Clinical Investigation Centre and Department of Clinical Pharmacology, Toulouse</wicri:regionArea><placeName><region type="region">Occitanie (région administrative)</region><region type="old region">Midi-Pyrénées</region><settlement type="city">Toulouse</settlement></placeName></affiliation><affiliation wicri:level="3"><country xml:lang="fr">France</country><wicri:regionArea>INSERM U455, Toulouse</wicri:regionArea><placeName><region type="region">Occitanie (région administrative)</region><region type="old region">Midi-Pyrénées</region><settlement type="city">Toulouse</settlement></placeName></affiliation></author><author><name sortKey="Montastruc, Jean Ouis" sort="Montastruc, Jean Ouis" uniqKey="Montastruc J" first="Jean-Louis" last="Montastruc">Jean-Louis Montastruc</name><affiliation wicri:level="3"><country xml:lang="fr">France</country><wicri:regionArea>Clinical Investigation Centre and Department of Clinical Pharmacology, Toulouse</wicri:regionArea><placeName><region type="region">Occitanie (région administrative)</region><region type="old region">Midi-Pyrénées</region><settlement type="city">Toulouse</settlement></placeName></affiliation></author></analytic><monogr></monogr><series><title level="j">Annals of Neurology</title><title level="j" type="sub">Official Journal of the American Neurological Association and the Child Neurology Society</title><title level="j" type="abbrev">Ann Neurol.</title><idno type="ISSN">0364-5134</idno><idno type="eISSN">1531-8249</idno><imprint><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><pubPlace>New York</pubPlace><date type="published" when="2003">2003</date><biblScope unit="volume">53</biblScope><biblScope unit="issue">S3</biblScope><biblScope unit="supplement">3</biblScope><biblScope unit="page" from="S3">S3</biblScope><biblScope unit="page" to="S15">S15</biblScope></imprint><idno type="ISSN">0364-5134</idno></series><idno type="istex">8375DC24A4BC4E9A05F5C375BBB7AB996C46D84E</idno><idno type="DOI">10.1002/ana.10513</idno><idno type="ArticleID">ANA10513</idno></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0364-5134</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Agonist</term><term>Amine oxidase (flavin-containing)</term><term>Antiparkinson Agents (adverse effects)</term><term>Antiparkinson Agents (classification)</term><term>Antiparkinson Agents (therapeutic use)</term><term>Antiparkinson agent</term><term>Catechol O-methyltransferase</term><term>Chemotherapy</term><term>Cognition Disorders (chemically induced)</term><term>Dopamine agonist</term><term>Dopamine receptor</term><term>Drug Resistance</term><term>Dysarthria (chemically induced)</term><term>Dyskinesia, Drug-Induced (etiology)</term><term>Electric Stimulation Therapy (methods)</term><term>Enzyme inhibitor</term><term>Globus Pallidus (physiology)</term><term>Globus Pallidus (surgery)</term><term>Human</term><term>Humans</term><term>Indication</term><term>Levodopa</term><term>MAO B inhibitor</term><term>Neurosurgical Procedures</term><term>Parkinson Disease (drug therapy)</term><term>Parkinson Disease (surgery)</term><term>Parkinson Disease (therapy)</term><term>Parkinson disease</term><term>Psychoses, Substance-Induced (etiology)</term><term>Quality of Life</term><term>Selegiline</term><term>Subthalamic Nucleus (physiology)</term><term>Subthalamic Nucleus (surgery)</term><term>Surgery</term><term>Toxicity</term><term>Treatment</term></keywords><keywords scheme="MESH" type="chemical" qualifier="adverse effects" xml:lang="en"><term>Antiparkinson Agents</term></keywords><keywords scheme="MESH" type="chemical" qualifier="classification" xml:lang="en"><term>Antiparkinson Agents</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Antiparkinson Agents</term></keywords><keywords scheme="MESH" qualifier="chemically induced" xml:lang="en"><term>Cognition Disorders</term><term>Dysarthria</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Parkinson Disease</term></keywords><keywords scheme="MESH" qualifier="etiology" xml:lang="en"><term>Dyskinesia, Drug-Induced</term><term>Psychoses, Substance-Induced</term></keywords><keywords scheme="MESH" qualifier="methods" xml:lang="en"><term>Electric Stimulation Therapy</term></keywords><keywords scheme="MESH" qualifier="physiology" xml:lang="en"><term>Globus Pallidus</term><term>Subthalamic Nucleus</term></keywords><keywords scheme="MESH" qualifier="surgery" xml:lang="en"><term>Globus Pallidus</term><term>Parkinson Disease</term><term>Subthalamic Nucleus</term></keywords><keywords scheme="MESH" qualifier="therapy" xml:lang="en"><term>Parkinson Disease</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Drug Resistance</term><term>Humans</term><term>Neurosurgical Procedures</term><term>Quality of Life</term></keywords><keywords scheme="Pascal" xml:lang="fr"><term>Agoniste</term><term>Amine oxidase (flavin-containing)</term><term>Antiparkinsonien</term><term>Catechol O-methyltransferase</term><term>Chimiothérapie</term><term>Chirurgie</term><term>Homme</term><term>IMAO B</term><term>Indication</term><term>Inhibiteur enzyme</term><term>Lévodopa</term><term>Parkinson maladie</term><term>Récepteur dopaminergique</term><term>Stimulant dopaminergique</term><term>Sélégiline</term><term>Toxicité</term><term>Traitement</term></keywords><keywords scheme="Wicri" type="topic" xml:lang="fr"><term>Chirurgie</term><term>Homme</term></keywords></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Levodopa and other dopaminergic medications drastically improve the motor symptoms and quality of life of patients with Parkinson's disease in the early stages of the disease. However, once the “honeymoon” period has waned, usually after a few years of dopaminergic therapy, patients become progressively more disabled despite an ever more complex combination of available antiparkinsonian treatments. Sooner or later, they suffer from “dopa‐resistant” motor symptoms (speech impairment, abnormal posture, gait and balance problems), “dopa‐resistant” nonmotor signs (autonomic dysfunction, mood and cognitive impairment, sleep problems, pain) and/or drug‐related side effects (especially psychosis, motor fluctuations, and dyskinesias). Therefore, the current antiparkinsonian therapy cannot be considered as ideal with regard to both efficacy and safety. Ann Neurol 2003;53 (suppl 3):S3–S15</div></front></TEI><affiliations><list><country><li>France</li><li>Portugal</li></country><region><li>Midi-Pyrénées</li><li>Occitanie (région administrative)</li></region><settlement><li>Toulouse</li></settlement></list><tree><country name="France"><region name="Occitanie (région administrative)"><name sortKey="Rascol, Olivier" sort="Rascol, Olivier" uniqKey="Rascol O" first="Olivier" last="Rascol">Olivier Rascol</name></region><name sortKey="Brefel Ourbon, Christine" sort="Brefel Ourbon, Christine" uniqKey="Brefel Ourbon C" first="Christine" last="Brefel-Courbon">Christine Brefel-Courbon</name><name sortKey="Brefel Ourbon, Christine" sort="Brefel Ourbon, Christine" uniqKey="Brefel Ourbon C" first="Christine" last="Brefel-Courbon">Christine Brefel-Courbon</name><name sortKey="Ferreira, Joaquim J" sort="Ferreira, Joaquim J" uniqKey="Ferreira J" first="Joaquim J." last="Ferreira">Joaquim J. Ferreira</name><name sortKey="Montastruc, Jean Ouis" sort="Montastruc, Jean Ouis" uniqKey="Montastruc J" first="Jean-Louis" last="Montastruc">Jean-Louis Montastruc</name><name sortKey="Ory, Fabienne" sort="Ory, Fabienne" uniqKey="Ory F" first="Fabienne" last="Ory">Fabienne Ory</name><name sortKey="Payoux, Pierre" sort="Payoux, Pierre" uniqKey="Payoux P" first="Pierre" last="Payoux">Pierre Payoux</name><name sortKey="Payoux, Pierre" sort="Payoux, Pierre" uniqKey="Payoux P" first="Pierre" last="Payoux">Pierre Payoux</name><name sortKey="Rascol, Olivier" sort="Rascol, Olivier" uniqKey="Rascol O" first="Olivier" last="Rascol">Olivier Rascol</name><name sortKey="Rascol, Olivier" sort="Rascol, Olivier" uniqKey="Rascol O" first="Olivier" last="Rascol">Olivier Rascol</name></country><country name="Portugal"><noRegion><name sortKey="Ferreira, Joaquim J" sort="Ferreira, Joaquim J" uniqKey="Ferreira J" first="Joaquim J." last="Ferreira">Joaquim J. Ferreira</name></noRegion></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/ParkinsonFranceV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 003132 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 003132 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= ParkinsonFranceV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= ISTEX:8375DC24A4BC4E9A05F5C375BBB7AB996C46D84E
|texte= Limitations of current Parkinson's disease therapy
}}
| This area was generated with Dilib version V0.6.29. |  |